Interview with Jacques Servier, Founder, Servier France
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Address: 22, Rue Garnier 92200 Neuilly sur Seine,France
Tel: +33 (0)1 55 72 60 00
Our entire activity is based on three key principles:
• Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
• Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
• Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
Figures
• Leading French independent pharmaceutical company
• Second French pharmaceutical company worldwide
• SERVIER is established in 140 countries
• 85% of SERVIER’s sales are achieved internationally
• Consolidated turnover for the 2007/2008 financial year: €3.7 billion
• More than 25% of SERVIER’s turnover is invested in Research and Development
• Worldwide workforce of over 20 000, including nearly 3 000 in Research and Development
• SERVIER contributes 29% of the trade surplus of France’s pharmaceutical industry
Osteoporosis
Diabetes
Cardiovascular
Venous Diseases
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Emmanuelle Ribot-Mariotte, general manager of Alfa Wassermann Pharma France, reveals how over the past year the company has been working hard on a new innovative treatment for hepatic encephalopathy, Rifaximin-alpha…
Finding success in the shadows of Big Pharma and large research facilities, CleveXel serves as a bridge in the industry, specializing on selecting promising molecules for investment, and developing them…
Prof. Thierry Philip, President of Institut Curie, is proud of the model that the institute is thriving for: excellent science and research in all forms, from the most basic to…
The recently appointed general manager of Galderma France, reveals the company’s ambitious objective for the next ten years: to increase sales from two to ten billion Euros (2.18 billion USD to…
Eric Goupil reveals how the global CMO market has expanded considerably over recent years, with a move towards a more strategic mind-set in the pharmaceutical industry. Unither´s business model is…
The presence in France of Swiss medical compression garment manufacturer Sigvaris dates back more than 100 years. The current president, Alain Bertheas, describes the company’s history and explains its garments.…
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through…
Arnaud Pradel, Product Development Director and Co-Segment Leader of HORIBA Medical reveals how HORIBA has over 30 years of experience when it comes to launching products in the vitro diagnostic…
The president of the family-run Laboratoires Panpharma, a specialist in injectable drugs for the hospital sector, reveals how they have affiliates in both France and Germany, are in the process of…
Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are…
Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system…
See our Cookie Privacy Policy Here
